Headlines about Osiris Therapeutics (NASDAQ:OSIR) have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Osiris Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.8995332422572 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Osiris Therapeutics (NASDAQ OSIR) opened at 5.35 on Tuesday. The company has a 50-day moving average of $6.10 and a 200 day moving average of $5.65. Osiris Therapeutics has a 52 week low of $2.67 and a 52 week high of $7.39. The firm has a market capitalization of $184.32 million, a P/E ratio of 127.38 and a beta of 0.79.
COPYRIGHT VIOLATION NOTICE: This news story was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/09/19/osiris-therapeutics-osir-receives-daily-news-sentiment-score-of-0-22.html.
About Osiris Therapeutics
Osiris Therapeutics, Inc is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing.
Receive News & Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.